Mike Doustdar

Mike Doustdar, the newly appointed CEO of Novo Nordisk, faces the challenge of disappointing sales for their key drugs, Wegovy and Ozempic. He discusses strategic priorities, including expanding patient access and the rationale behind the recent acquisition of Metzera to enhance their product offerings. Doustdar also touches on competitive dynamics with Eli Lilly and emphasizes the importance of adapting to patient preferences between pills and injections. Additionally, he shares insights into engaging with the U.S. administration on pricing negotiations.